Amyloid pathology in cognitively normal elderly subjects (PreclinAD)

• A potential participant who meets any of the following criteria will be excluded from participation in this study:  Clinical diagnosis of mild cognitive impairment or probable AD  Severe head trauma, with loss of consciousness  Brain tumour (past, present)  Schizophrenia, bipolar disorders, or recurrent psychotic disorders  Stroke resulting in physical impairment  Neurodegenerative disorders (e.g. Huntington disease, cortical basal degeneration, multiple system atrophy, Creutzfeldt-Jacob disease, primary progressive aphasia, Parkinson’s disease)  Epilepsy, currently using antiepileptic drugs (AEDs)  Brain infection (e.g. herpes simplex encephalitis)  Cancer with terminal life expectancy  Known B12 vitamin deficiency without treatment  Uncontrolled diabetes mellitus  Known thyroid disease without treatment  History of recreational drug use  Alcohol consumption: >35 units per week  Physical morbidity or illness which will not permit attendance at visit sessions  Contraindication for MRI (e.g. metal implants, pacemaker etc.)  Medications that may impair cognition, at the discretion of the investigator, e.g.: o High dose benzodiazepine o Lithium carbonate o Antipsychotics including atypical agents o High dose antidepressants o Parkinson’s disease medicines

Contact the study team to confirm eligibility.